RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
92 hedge funds and large institutions have $160M invested in RAPT Therapeutics in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 15 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
1% more funds holding
Funds holding: 91 → 92 (+1)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
20% less capital invested
Capital invested by funds: $199M → $160M (-$39.5M)
32.95% less ownership
Funds ownership: 45.37% → 12.42% (-33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.56M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$5.9M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.63M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$725K |
| 5 |
Renaissance Technologies
New York
|
+$343K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.39M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.8M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$1.58M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$909K |
| 5 |
D.E. Shaw & Co
New York
|
-$843K |
RAPT Hedge Fund Activity: Q1 2025 in Review
92 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2025, worth a combined $160M — down 20% from $199M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RAPT positions and 15 closed out — a net gain of 1 holder — while 27 added to existing stakes and 25 trimmed.
The largest buyer was Vanguard Group, adding an estimated $6.56M. The largest seller was Fidelity Investments, cutting an estimated $6.39M.
- 92 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2025, up from 91 in Q4 2024.
- Funds reported $160M of RAPT Therapeutics stock for Q1 2025, down 20% quarter-over-quarter.
- 16 funds opened new RAPT Therapeutics positions in Q1 2025 and 15 closed out, a net change of +1 holder.
- The largest RAPT Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $6.56M added.
- The largest RAPT Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $6.39M sold.
Based on aggregated 13F filings for Q1 2025.